Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803
- Authors:
- Yu-Bin Wang
- Jun-Hong Liu
- Zong-Min Song
View Affiliations
Affiliations: Department of General Surgery, The First Affiliated Hospital, Liaoning Medical University, Jinzhou 121001, P.R. China
- Published online on: August 13, 2012 https://doi.org/10.3892/br.2012.3
-
Pages:
77-79
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The present study aimed to explore the effects of recombinant human endostatin, endostar (ES), on the expression of vascular endothelial growth factor (VEGF) in the human gastric cancer cell line MGC-803. The expression of VEGF protein in MGC-803 cells was examined using immunohistochemistry. Subsequent to treatment with various concentrations of ES, the mRNA and VEGF protein expressions were determined in MGC-803 cells. A high level of VEGF protein expression was detected in MGC-803 cells. Subsequent to ES treatment, the mRNA and VEGF protein expressions were significantly decreased in MGC-803 cells (all P<0.05). In conclusion, ES is likely to inhibit the VEGF expression in MGC-803 cells.
View References
|
1.
|
He XW, Yu X, Liu T, Yu SY and Chen DJ:
Vector-based RNA interference against vascular endothelial growth
factor C inhibits tumor lymph angiogenesis and growth of colorectal
cancer in vivo in mice. Chin Med J (Engl). 121:439–444. 2008.
|
|
2.
|
Satchi-Fainoaro R, Puder M, Davies JW,
Tran HT, Sampson DA, Greene AK, Corfas G and Folkman J: Targeting
angiogenesis with a conjugate of H PMA copolymer and TNP-470. Nat
Med. 10:255–261. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Tian XJ, Wu J and Meng L: Preparation of
monoclonal antibodies to human vascular endothelial growth factor
(VEGF 121) and identification of its expression on gastric
carcinoma cell line MGC803. Zhonghua Zhong Liu Za Zhi. 21:93–95.
1999.(In Chinese).
|
|
4.
|
Luo XD, Xin Y and Xiao YP: Expression of
VEGF and its receptors Flt-1 and KDR in gastric carcinoma and its
significance. J Chin Med Univ. 37:760–763. 2008.(In Chinese).
|
|
5.
|
Xu HR, Tian W, Niu XH, Yuan RY, Zhang Q,
Chen DF and Liu WF: In vitro study of recombinant human endostatin
in combination with adriamycin on human osteosarcoma cell OS-732.
Chin J Bone Tumor Bone Dis. 7:129–132. 2008.(In Chinese).
|
|
6.
|
Neskey DM, Ambesi A, Pumiglia KM and
McKeown-Longo PJ: Endostatin and anastellin inhibit distinct
aspects of the angiogenic process. J Exp Clin Cancer Res.
27:612008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Wu XZ: New strategy of antiangiogenic
therapy for hepatocellular carcinoma. Neoplasma. 55:472–481.
2008.PubMed/NCBI
|
|
8.
|
Franco TH, Khan A, Joshi V and Thomas B:
Takotsubo cardiomyopathy in two men receiving bevacizumab for
metastatic cancer. Ther Clin Risk Manag. 4:1367–1370.
2008.PubMed/NCBI
|
